### Vincristine

**Indication**  
Lymphoid leukaemia, not elsewhere classified  
**ICD11 code:** 2C03.3

**INN**  
Vincristine

**Medicine type**  
Chemical agent

**List type**  
Complementary

**Formulations**  
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)

**EML status history**  
First added in 2011 (TRS 965)  
Changed in 2015 (TRS 994)  
Changed in 2021 (TRS 1035)

**Sex**  
All

**Age**  
Also recommended for children

**Therapeutic alternatives**  
The recommendation is for this specific medicine

**Patent information**  
Patents have expired in most jurisdictions  
Read more about patents.

**Tags**  
Cancer

**Wikipedia**  
[Vincristine](https://en.wikipedia.org/wiki/Vincristine)

**DrugBank**  
[Vincristine](https://www.drugbank.ca/drugs/DB_000116)

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1 mg/mL and 2 mg/2 mL) to the EML and EMLc.